January 2025 :
The SUCCOUR-MRI trial assessed whether cardioprotective therapy guided by early detection of reduced global longitudinal strain (GLS) during anthracycline chemotherapy could better preserve left ventricular ejection fraction (LVEF). In 333 patients, those with isolated GLS impairment received either cardioprotective therapy or usual care. Results showed that cardioprotective therapy significantly reduced declines in LVEF. Its potential to improve cardiovascular clinical outcomes needs further research.
- Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial
- Breast cancer and cardiovascular health
December 2024 :
Authors explore pathways of myocyte toxicity due to antharcyclines by means of a translational study including a murine animal model and replicated on cardiomyocytes from a single leukemia patient. Their results increase our knowledge on the pathways of anthracyclin cardiotoxicity. Authors test the effect of IL-1α neutralizing antibodies with a positive effect on the murine model. Although their results need further research in humans, it opens new perspectives for cardioprotection beyond the classic heart failure therapies.
- Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study
- Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer
November 2024 :
- Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score
- Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)
Our mission: To reduce the burden of cardiovascular disease.